Taming the dragon: genomic biomarkers to individualiz

Nature Medicine

17, 304-312

DOI: 10.1038/nm.2311

Citation Report

#	Article	IF	Citations
1	Grand Challenges in Computational Physiology and Medicine. Frontiers in Physiology, 2011, 2, 79.	1.3	12
3	Somatic variation and cancer: therapies lost in the mix. Human Genetics, 2011, 130, 79-91.	1.8	40
4	Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases. Future Medicinal Chemistry, 2011, 3, 1647-1662.	1.1	17
5	Cancer Vaccines: Personalizing Health Interventions. Current Pharmacogenomics and Personalized Medicine, 2011, 9, 208-228.	0.2	1
6	The Use of Immunohistochemistry for Biomarker Assessmentâ€"Can It Compete with Other Technologies?. Toxicologic Pathology, 2011, 39, 988-1002.	0.9	85
7	Multigene and multitests: current trend and implications of genetic biomarkers for personalized medicine. Personalized Medicine, 2012, 9, 561-564.	0.8	0
8	The paradigm of personalized therapy in oncology. Expert Opinion on Therapeutic Targets, 2012, 16, S7-S16.	1.5	17
11	Multiscale Integration of -Omic, Imaging, and Clinical Data in Biomedical Informatics. IEEE Reviews in Biomedical Engineering, 2012, 5, 74-87.	13.1	48
12	Cancer biomarkers: selecting the right drug for the right patient. Nature Reviews Drug Discovery, 2012, 11, 201-214.	21.5	225
13	Differences in the quantity of DNA found in the urine and saliva of smokers versus nonsmokers: implications for the timing of epigenetic events. Epigenomics, 2012, 4, 343-352.	1.0	22
14	Mining proteomic data for biomedical research. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 2012, 2, 1-13.	4.6	11
15	High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway. Clinical Cancer Research, 2012, 18, 1374-1385.	3.2	165
17	Metastatic disease: A drug discovery perspective. Seminars in Cancer Biology, 2012, 22, 261-271.	4.3	7
18	New Advances on Disease Biomarkers and Molecular Targets in Biomedicine. , 2013, , .		0
19	Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome. BMC Cancer, 2013, 13, 344.	1.1	24
20	Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 887-898.	0.9	80
22	Targeting tyrosine-kinases in ovarian cancer. Expert Opinion on Investigational Drugs, 2013, 22, 1265-1279.	1.9	23
23	Challenges and opportunities for oncology biomarker discovery. Drug Discovery Today, 2013, 18, 614-624.	3.2	44

#	Article	IF	Citations
24	The progress of proteomic approaches in searching for cancer biomarkers. New Biotechnology, 2013, 30, 319-326.	2.4	16
25	Biomarkers. , 2013, , 317-352.		7
26	TGF-Î²: An emerging player in drug resistance. Cell Cycle, 2013, 12, 2960-2968.	1.3	117
28	Can Only Physical Subject-Matter Be Patentable?. SSRN Electronic Journal, 2013, , .	0.4	0
29	Activities of multiple cancer-related pathways are associated withBRAFmutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. Cell Cycle, 2014, 13, 208-219.	1.3	31
30	Translation Strategy for the Qualification of Drug-induced Vascular Injury Biomarkers. Toxicologic Pathology, 2014, 42, 658-671.	0.9	13
31	Clinical value of DNA content assessment in endometrial cancer. , 2014, 86, 154-163.		13
32	Microfluidic platforms for biomarker analysis. Lab on A Chip, 2014, 14, 1496-1514.	3.1	116
33	Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer. Clinical Cancer Research, 2014, 20, 1428-1444.	3.2	81
34	Oncology Drug Discovery: Planning a Turnaround. Cancer Discovery, 2014, 4, 397-404.	7.7	50
35	Histone H1 Phosphorylation in Breast Cancer. Journal of Proteome Research, 2014, 13, 2453-2467.	1.8	38
36	Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelialâ€“mesenchymal transition and PI3K alterations. Gynecologic Oncology, 2014, 134, 599-606.	0.6	8
37	Boosting for high-dimensional two-class prediction. BMC Bioinformatics, 2015, 16, 300.	1.2	20
38	The Assessment of the Readiness of Molecular Biomarker-Based Mobile Health Technologies for Healthcare Applications. Scientific Reports, 2015, 5, 17854.	1.6	15
40	Test set bias affects reproducibility of gene signatures. Bioinformatics, 2015, 31, 2318-2323.	1.8	90
41	Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial. Journal of Clinical Oncology, 2015, 33, 1000-1007.	0.8	206
42	Impact of Biomarkers on Personalized Medicine. Handbook of Experimental Pharmacology, 2015, 232, 285-311.	0.9	11
43	Homogeneous Biosensing Based on Magnetic Particle Labels. Sensors, 2016, 16, 828.	2.1	75

#	Article	IF	Citations
44	Development of Electrochemical Immunosensors towards Pointâ€ofâ€care Cancer Diagnostics: Clinically Relevant Studies. Electroanalysis, 2016, 28, 1716-1729.	1.5	35
45	Systems Pharmacology and Pharmacodynamics. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , .	0.2	9
46	Machine Learning for Health Informatics. Lecture Notes in Computer Science, 2016, , .	1.0	27
47	Machine Learning for In Silico Modeling of Tumor Growth. Lecture Notes in Computer Science, 2016, , 415-434.	1.0	7
48	Using Systems Pharmacology to Advance Oncology Drug Development. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 421-463.	0.2	1
49	New Approaches to Drug Discovery. Handbook of Experimental Pharmacology, 2016, , .	0.9	5
50	Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?. Cancer Biotherapy and Radiopharmaceuticals, 2016, 31, 75-84.	0.7	14
51	Reflection of successful anticancer drug development processes in the literature. Drug Discovery Today, 2016, 21, 1740-1744.	3.2	11
53	Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens. Scientific Reports, 2016, 6, 33968.	1.6	11
54	Toward Analysis of Proteins in Single Cells: A Quantitative Approach Employing Isobaric Tags with MALDI Mass Spectrometry Realized with a Microfluidic Platform. Analytical Chemistry, 2016, 88, 6672-6679.	3.2	39
55	Transcriptomics and Gene Regulation. Translational Bioinformatics, 2016, , .	0.0	2
56	Translational research in surgical oncology. British Journal of Surgery, 2017, 104, 491-492.	0.1	4
58	Foretelling Graft Outcome by Molecular Evaluation of Renal Allograft Biopsies. Transplantation, 2017, 101, 5-7.	0.5	2
60	Inference for multimarker adaptive enrichment trials. Statistics in Medicine, 2017, 36, 4083-4093.	0.8	15
62	Gradient boosting for high-dimensional prediction of rare events. Computational Statistics and Data Analysis, 2017, 113, 19-37.	0.7	50
63	Microphysiometry. Bioanalytical Reviews, 2018, , 163-188.	0.1	2
64	The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities. Expert Review of Molecular Diagnostics, 2018, 18, 133-145.	1.5	92
65	What (not) to expect when classifying rare events. Briefings in Bioinformatics, 2018, 19, 341-349.	3.2	5

#	Article	IF	Citations
66	Using ddPCR to assess the DNA yield of FFPE samples. Biomolecular Detection and Quantification, 2018, 16, 5-11.	7.0	12
67	Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. BMC Cancer, 2019, 19, 1025.	1.1	7
69	Decrypting the electrophysiological individuality of the human brain: Identification of individuals based on resting-state EEG activity. NeuroImage, 2019, 197, 470-481.	2.1	34
70	Label-Free Monitoring of Cells in vitro. Bioanalytical Reviews, 2019, , .	0.1	3
71	Recent advances in single cell manipulation and biochemical analysis on microfluidics. Analyst, The, 2019, 144, 766-781.	1.7	119
72	A Novel Label Free Electrochemical Magnetoimmunosensor for Human Interleukinâ€6 Quantification in Serum. Electroanalysis, 2019, 31, 282-292.	1.5	15
73	Prognostic Molecular Indices of Resectable Hepatocellular Carcinoma: Implications of S100P for Early Recurrence. Annals of Surgical Oncology, 2021, 28, 6466-6478.	0.7	6
74	Precision medicine and the principle of equal treatment: a conjoint analysis. BMC Medical Ethics, 2021, 22, 55.	1.0	7
75	FRL: An Integrative Feature Selection Algorithm Based on the Fisher Score, Recursive Feature Elimination, and Logistic Regression to Identify Potential Genomic Biomarkers. BioMed Research International, 2021, 2021, 1-16.	0.9	4
76	Min-Max Optimal Design of Two-Armed Trials with Side Information. INFORMS Journal on Computing, 0, , .	1.0	2
77	2dFDR: a new approach to confounder adjustment substantially increases detection power in omics association studies. Genome Biology, 2021, 22, 208.	3.8	2
78	Identification of Biomarkers for Pharmacological Activity. Translational Bioinformatics, 2013, , 189-205.	0.0	1
79	Microfluidics-Mass Spectrometry Combination Systems for Single-Cell Analysis. Integrated Analytical Systems, 2019, , 163-195.	0.4	2
81	Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Genes and Cancer, 2016, 7, 301-308.	0.6	15
82	Molecular Portrait of Clear Cell Renal Cell Carcinoma: An Integrative Analysis of Gene Expression and Genomic Copy Number Profiling. , 0, , .		0
83	Using Genomic Biomarkers to Predict Patient Prognosis and Treatment Response in Gastric Cancer. , 2013, , 105-136.		1
84	Hinweise zur Studienplanung,Biometrie und klinischen Epidemiologie. , 2014, , 117-136.		0
85	Molekularbiologische Untersuchungen bei multipler Sklerose. , 2015, , 211-214.		0

#	Article	IF	Citations
86	Computing the Cure to Cancer. California Agriculture, 2015, 20, .	0.0	0
87	Systematic and Integrative Analysis of Gene Expression to Identify Feature Genes Underlying Human Diseases. Translational Bioinformatics, 2016, , 161-185.	0.0	0
88	An immunohistochemical study of histone H1.5 in correlation with clinicopathologic features of invasive duct carcinoma (not otherwise specified). Egyptian Journal of Pathology, 2017, 37, 339-344.	0.0	0
89	Hinweise zur Studienplanung,Biometrie und klinischen Epidemiologie. , 2014, , 117-136.		0
90	Modeling factors critical for implementation of precision medicine at health systems-level: an IRT approach.. American Journal of Translational Research (discontinued), 2021, 13, 12557-12574.	0.0	0
91	Epithelial TGFÎ² engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nature Communications, 2022, 13, .	5.8	2